Email this article 
Hide
Show all
Guideline
Fixed-dose combination for adults accessing antiretroviral therapy
Submitted: 12 December 2013 | Published: 26 February 2013
About the author(s)
SA HIV Clinicians Society, SA HIV Clinicians Society, Johannesburg, South AfricaAbstract
Summary
Transitioning from individual drugs to an FDC tablet needs to be managed carefully, particularly regarding stock management, ordering processes, supply-chain integrity and comprehensive patient counselling.
Priority groups
• Initially, FDC supply will be insufficient to provide for all FDC-suitable patients
• Therefore, the National Department of Health (NDoH) has recommended that the following patient groups be prioritized for FDC initiation/switch:
• Priority group 1: All HIV-positive patients newly initiating ART – adults, adolescents and pregnant women (regardless of CD4 count (amendment to the guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) anticipated in April 2013) – and who do not have contra-indications to the FDC component drugs
• Priority group 2: HIV-positive pregnant women and breastfeeding mothers currently stable on lamivudine (3TC), TDF and EFV
• Priority group 3: Virologically suppressed patients on a stavudine (d4T)-based regimen and who have normal renal function
• Priority group 4: Stable patients receiving individual TDF, 3TC and EFV and who have tuberculosis (TB) co-infection
• Priority group 5: Stable patients receiving individual TDF, 3TC and EFV and who have other co-morbidites (e.g. hypertension, diabetes)
• Priority group 6: Patients receiving individual TDF, 3TC and EFV and who request to switch to the FDC treatment
• Priority group 7: Patients receiving individual TDF, 3TC and EFV and who, after counselling, agree to switch to the FDC treatment.
Important: Clinic staff must co-ordinate this process and only switch as many patients to the FDC tablet as stock allows. This should avoid patients being switched back and forth between FDC and individual drugs due to insufficient stock.
Note: The FDC tablet is not significantly larger than EFV or lopinavir/ritonavir (LOP/r) (Aluvia); therefore, swallowing should not be problematic.
S Afr J HIV Med 2013;14(1 Suppl):41-43. DOI:10.7196/SAJHIVMED.913
Keywords
Metrics
Total abstract views: 6462Total article views: 61708
Crossref Citations
1. Pharmaco-Audiology Vigilance in the Treatment of Adult Patients with HIV/Aids: Ototoxicity Monitoring Protocol Recommendation
Katijah Khoza-Shangase
Infectious Disorders - Drug Targets vol: 20 issue: 1 first page: 33 year: 2020
doi: 10.2174/1871526518666181016102102
2. An Efficient Sensor for the Detection of Zidovudine Based on 1‐Ethyl‐3‐methylimidazolium 1,1,2,2‐tetrafluoroethanesulfonate/ZnO Nanoparticle/MWCNT Glassy Carbon Electrodes**
Nokukhanya Mavis Xhakaza, Rajasekhar Chokkareddy, Gan G Redhi
ChemistrySelect vol: 6 issue: 46 first page: 13309 year: 2021
doi: 10.1002/slct.202102531
3. Cost-savings accruable to removing value added tax from antiretrovirals in the South African private health sector
Varsha Bangalee, Fatima Suleman
Health SA Gesondheid vol: 22 first page: 150 year: 2017
doi: 10.1016/j.hsag.2016.11.003
4. Improvements in the South African HIV care cascade: findings on 90‐90‐90 targets from successive population‐representative surveys in North West Province
Sheri A Lippman, Alison M El Ayadi, Jessica S Grignon, Adrian Puren, Teri Liegler, W D Francois Venter, Mary J Ratlhagana, Jessica L Morris, Evasen Naidoo, Emily Agnew, Scott Barnhart, Starley B Shade
Journal of the International AIDS Society vol: 22 issue: 6 year: 2019
doi: 10.1002/jia2.25295
5. Parenting the child with HIV in limited resource communities in South Africa: mothers with HIV’s emotional vulnerability and hope for the future
Malerato Moshoeshoe, Sphiwe Madiba
Women's Health vol: 17 year: 2021
doi: 10.1177/17455065211058565
6. Provision of Antiretroviral Therapy in South Africa: The Nuts and Bolts
Linda-Gail Bekker, Francois Venter, Karen Cohen, Eric Goemare, Gilles Van Cutsem, Andrew Boulle, Robin Wood
Antiviral Therapy vol: 19 issue: 3_suppl first page: 105 year: 2014
doi: 10.3851/IMP2905
7. DNA polymerase-γ hypothesis in nucleoside reverse transcriptase-induced mitochondrial toxicity revisited: A potentially protective role for citrus fruit-derived naringenin?
Mathabo Ruth Lutu, Sanelisiwe Nzuza, Pascale Edith Mofo Mato, Khmera Govender, Londiwe Mphumelelo Gumede, Sinenhlanhla Innocentia Kumalo, Nontokozo Nomfundo Mlambo, Ranjendraparsad Hurchund, Peter Mark Oroma Owira
European Journal of Pharmacology vol: 852 first page: 159 year: 2019
doi: 10.1016/j.ejphar.2019.03.017
8. Spatiotemporal Variation and Predictors of Unsuppressed Viral Load among HIV-Positive Men and Women in Rural and Peri-Urban KwaZulu-Natal, South Africa
Adenike O. Soogun, Ayesha B. M. Kharsany, Temesgen Zewotir, Delia North, Ebenezer Ogunsakin, Perry Rakgoale
Tropical Medicine and Infectious Disease vol: 7 issue: 9 first page: 232 year: 2022
doi: 10.3390/tropicalmed7090232
9. Mechanochemical synthesis and characterization of Zidovudine-lamivudine solid dispersion (binary eutectic mixture)
Jean Baptiste Ngilirabanga, Marique Aucamp, Halima Samsodien
Journal of Drug Delivery Science and Technology vol: 64 first page: 102639 year: 2021
doi: 10.1016/j.jddst.2021.102639
10. Prevention of mother-to-child transmission in South Africa: an ever-changing landscape
Rosie Burton, Janet Giddy, Kathryn Stinson
Obstetric Medicine vol: 8 issue: 1 first page: 5 year: 2015
doi: 10.1177/1753495X15570994
11. Realist evaluation of the antiretroviral treatment adherence club programme in selected primary healthcare facilities in the metropolitan area of Western Cape Province, South Africa: a study protocol
Ferdinand C Mukumbang, Sara Van Belle, Bruno Marchal, Brian Van Wyk
BMJ Open vol: 6 issue: 4 first page: e009977 year: 2016
doi: 10.1136/bmjopen-2015-009977